10 Most Expensive Drugs on the Market
Zolgensma (onasemnogene abeparvovec): A gene therapy for spinal muscular atrophy, Zolgensma costs approximately $2.1 million per treatment.
Luxturna (voretigene neparvovec): Used to treat inherited retinal diseases, Luxturna is priced at around $850,000 per treatment.
Myalept (metreleptin): Prescribed for patients with lipodystrophy, Myalept is priced at approximately $71,306 per month.
Brineura (cerliponase alfa): A treatment for a form of Batten disease, Brineura costs around $702,000 per year.
Soliris (eculizumab): Used to treat rare blood disorders like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Heading 2
Heading 2
Heading 2
Glybera (alipogene tiparvovec): Initially priced at over $1 million per treatment, Glybera was one of the most expensive drugs ever marketed.
Heading 2
Heading 2
Heading 2
Kynamro (mipomersen): Prescribed to treat familial hypercholesterolemia, Kynamro costs around $176,000 per year
Heading 2
Heading 2
Heading 2
Firazyr (icatibant): Used to treat hereditary angioedema (HAE), Firazyr is priced at approximately $73,000 for a supply of three doses.
Heading 2
Heading 2
Heading 2
Naglazyme (galsulfase): Used to treat mucopolysaccharidosis type VI (MPS VI), Naglazyme costs around $485,747 per year.
Heading 2
Heading 2
Heading 2
Elaprase (idursulfase): Prescribed for the treatment of Hunter syndrome, Elaprase costs approximately $375,000 per year.
Heading 2
Heading 2
Heading 2
Click Here